Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion's Aspira Labs Secures Expanded Medi-Cal Coverage for OVA1

NEW YORK (GenomeWeb) – Vermillion said yesterday that its Aspira Labs subsidiary has won out-of-state provider status with Medi-Cal, California's Medicaid program, for its OVA1 ovarian cancer test.

The status gives the company access to more than 12 million Medi-Cal beneficiaries, representing roughly one-third of the covered lives in California, Vermillion said.

"This new status is an expansion to our prior Medi-Cal coverage and is key to reaching the entire Medicaid base, as well as expanding OVA1 access in the state with the largest US population," Valerie Palmieri, president and CEO of Vermillion, said in a statement. "It should also create additional opportunities with healthcare systems and other medical insurers in the California market."

OVA1 is a proteomic test intended for use in patients with an adnexal mass to determine prior to surgery whether the mass is likely malignant or benign and help physicians decide if a patient should be passed on to a gynecologic oncologist for the procedure.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.